Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 2/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | FLT3 | P36888 | 1/20 | 0.48 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.48 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.48 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.48 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.48 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.48 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.48 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 2/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | MET | P08581 | 1/20 | 0.43 |
| ▸ | CA12 | O43570 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | CA7 | P43166 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16275129 | 0.95 | EPHX2 (0.48) | ACHEFLT3PSEN1PSEN2APH1B | |
| Hydrochloric Acid SCHEMBL5439439 | 0.94 | EPHX2 (0.47) | ACHENPC1RAB9AFLT3PSEN1 | |
| SCHEMBL5194991 | 0.84 | MAPT (0.46) | TP53HRH3 | |
| SCHEMBL5439520 | 0.84 | MAPT (0.46) | HRH3 | |
| SCHEMBL5450888 | 0.83 | CCNC (0.41) | NPC1RAB9AKDM4EHRH3 | |
| SCHEMBL5439478 | 0.83 | MAPT (0.45) | TP53HRH2HRH1HRH3 | |
| SCHEMBL5439446 | 0.82 | MAPT (0.44) | ALDH1A1TP53HRH3 | |
| SCHEMBL8264094 | 0.81 | MAPT (0.47) | ALDH1A1TP53HRH3 | |
| SCHEMBL5445008 | 0.81 | MAPT (0.43) | ACHEPSEN1PSEN2APH1BNCSTN | |
| SCHEMBL5438385 | 0.80 | MAPK14 (0.45) | ACHEPSEN1PSEN2APH1BNCSTN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130109652-A1 | NOVEL PYRIDINONE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2-RECEPTORS | ADDEX PHARMACEUTICALS S.A. (CH) | 2013-05-02 | — | — | US | claimed |
| US-20130109652-A1 | NOVEL PYRIDINONE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2-RECEPTORS | ADDEX PHARMACEUTICALS S.A. (CH) | 2013-05-02 | — | — | US | disclosed |
| US-8399493-B2 | Pyridinone derivatives and their use as positive allosteric modulators of mGluR2-receptors | Janssen Pharmaceuticals, Inc. (US) | 2013-03-19 | — | — | US | disclosed |
| US-20070213323-A1 | NOVEL PYRIDINONE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2-RECEPTORS | Janssen Pharmaceuticals, Inc. | 2007-09-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070213323-A1 | NOVEL PYRIDINONE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2-RECEPTORS | GRM2, GRM1, GRM3 | ACHE 1552/4885NPC1 3587/4885RAB9A 1832/4885 |
| US-20130109652-A1 | NOVEL PYRIDINONE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2-RECEPTORS | GRM2, GRM1, GRIA2 | ACHE 1222/4885NPC1 3908/4885RAB9A 2044/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.